Extensive conformational and physical plasticity protects HER2-HER3 tumorigenic signaling
Open Access
- 1 February 2022
- journal article
- research article
- Published by Elsevier in Cell Reports
- Vol. 38 (5) , 110285
Abstract
No abstract availableKeywords
This publication has 70 references indexed in Scilit:
- Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitorsNature, 2012
- Structural Evidence for Loose Linkage between Ligand Binding and Kinase Activation in the Epidermal Growth Factor ReceptorMolecular and Cellular Biology, 2010
- The Therapeutic Effect of Anti-HER2/neu Antibody Depends on Both Innate and Adaptive ImmunityCancer Cell, 2010
- Protein-tyrosine Phosphatase PTPN9 Negatively Regulates ErbB2 and Epidermal Growth Factor Receptor Signaling in Breast Cancer CellsJournal of Biological Chemistry, 2010
- Resiliency and Vulnerability in the HER2-HER3 Tumorigenic DriverScience Translational Medicine, 2010
- Identity of the elusive IgM Fc receptor (FcμR) in humansJournal of Experimental Medicine, 2009
- The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesisOncogene, 2007
- Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complexCancer Cell, 2004
- Structure of the extracellular region of HER2 alone and in complex with the Herceptin FabNature, 2003
- Differential endocytic routing of homo‐ and hetero‐dimeric ErbB tyrosine kinases confers signaling superiority to receptor heterodimersThe EMBO Journal, 1998